Abstracts tagged "Lupus and antibodies"

Abstract Number: 1679 • 2018 ACR/ARHP Annual Meeting
Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies
Jordi Camins Fàbregas¹, Melania Martinez-Morillo¹, Aina Teniente-Serra², Anne Riveros³, Sergi Heredia³, Agueda Prior⁴, Susana Holgado¹, Lourdes Mateo¹, Maria Aparicio¹, Laia Gifre¹, Ivette Casafont-Solé¹, Yaiza Garcia¹, Gladys Juncà⁵, Roger Villuendas⁵, Antoni Bayés-Genis⁵, Eva Martínez-Cáceres² and Alejandro Olivé-Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Immunology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁵Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Cardiac block in neonatal lupus is associated with placental transfer of anti-Ro antibodies. The effect of these antibodies on cardiac conduction disorders in adult…
Abstract Number: 567 • 2013 ACR/ARHP Annual Meeting
Contribution Of Marginal Zone B Cells To Autoimmunity In The B6.Sle1.Sle2.Sle3 Lupus Prone Mouse
Ying Yi Zheng¹ and Laurence Morel², ¹Pathology, University of Florida, Gainesville, FL, ²Pathology/Immunology/Lab Medical, University of Florida, Gainesville, FL
Background/Purpose: We used the B6.Sle1.Sle2.Sle3 triple congenic (TC) mouse, which expresses three lupus susceptibility loci derived from NZM2410 onto the C57BL/6 (B6) background, to investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].